Plasma insulin, C-peptide and blood glucose and the risk of gastric cancer: The Japan Public Health Center-based prospective study

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages 1402-1410

  Hidaka, Akihisa ^a,b   Sasazuki, Shizuka ^a   Goto, Atsushi ^c   Sawada, Norie ^a   Shimazu, Taichi ^a   Yamaji, Taiki ^a   Iwasaki, Motoki ^a   Inoue, Manami ^a,d   Noda, Mitsuhiko ^c   Tajiri, Hisao ^b   Tsugane, Shoichiro ^a  

^a NATIONAL CANCER CENTER   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Gastric cancer risk; Plasma blood glucose; Plasma C peptide; Plasma insulin; Prospective study

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; JAPAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PROSPECTIVE STUDY; RISK FACTOR; STOMACH CANCER; ADVERSE EFFECTS; ANALYSIS; BLOOD; DRINKING BEHAVIOR; MIDDLE AGED; PUBLIC HEALTH; RISK; STOMACH NEOPLASMS;

ADULT; AGED; ALCOHOL DRINKING; BLOOD GLUCOSE; C-PEPTIDE; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PUBLIC HEALTH; RISK; STOMACH NEOPLASMS;

EID: 84922237880     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29098     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control 2012;23:967-81.
3. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-5.
4. Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006;166:1871-7.
5. Lin SW, Freedman ND, Hollenbeck AR, et al. Prospective study of self-reported diabetes and risk of upper gastrointestinal cancers. Cancer Epidemiol Biomarkers Prev 2011;20:954-61.
6. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012;55:948-58.
7. Wotton CJ, Yeates DG, Goldacre MJ. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia 2011;54:527-34.
8. Ogunleye AA, Ogston SA, Morris AD, et al. A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 2009;101:1199-201.
9. Chodick G, Heymann AD, Rosenmann L, et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 2010;21:879-87.
10. Khan M, Mori M, Fujino Y, et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev 2006;7:253-9.
11. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-14.
12. Atchison EA, Gridley G, Carreon JD, et al. Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer 2011;128:635-43.
13. Ikeda F, Doi Y, Yonemoto K, et al. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 2009;136:1234-41.
14. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202.
15. Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 2006;49:945-52.
16. Jun JK, Gwack J, Park SK, et al. Fasting serum glucose level and gastric cancer risk in a nested case-control study. J Prev Med Public Health 2006;39:493-8 (In Korean with English abstract).
17. Yi HK, Hwang PH, Yang DH, et al. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer 2001;37:2257-63.
18. Kasuga M, Ueki K, Tajima N, et al. Report of the Japan diabetes society/japanese cancer association joint committee on diabetes and cancer. Cancer Sci 2013;104:965-76.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
20. Watanabe S, Tsugane S, Sobue T, et al. Study design and organization of the JPHC study. Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J Epidemiol 2001;11:S3-S7.
21. Iida M, Sato S, Nakamura M. Standardization of laboratory test in the JPHC study. Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J Epidemiol 2001;11:S81-S6.
22. WHO. International classification of diseases for oncology. Geneva, Switzerland: World Health Organization, 2000.
23. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965;64:31-49.
24. Miki K, Morita M, Sasajima M, et al. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003;98:735-9.
25. Urita Y, Hike K, Torii N, et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci 2004;49:795-801.
26. Ohnishi H, Saitoh S, Takagi S, et al. Incidence of insulin resistance in obese subjects in a rural Japanese population: the Tanno and Sobetsu study. Diabetes Obes Metab 2005;7:83-7.
27. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85.
28. Stocks T, Rapp K, Bjørge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 2009;6:e1000201.
29. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008;114:63-70.
30. Wolpin BM, Bao Y, Qian ZR, et al. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 2013;105:1027-35.
31. Ollberding NJ, Cheng I, Wilkens LR, et al. Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the Multiethnic Cohort study. Cancer Epidemiol Biomarkers Prev 2012;21:810-20.
32. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109S-20S.
33. Camargo MC, Goto Y, Zabaleta J, et al. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:20-38.
34. Key TJ, Allen NE, Verkasalo PK, et al. Energy balance and cancer: the role of sex hormones. Proc Nutr Soc 2001;60:81-9.
35. Lindtner C, Scherer T, Zielinski E, et al. Binge drinking induces whole-body insulin resistance by impairing hypothalamic insulin action. Sci Transl Med 2013;5:170ra14.
36. Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. Lancet 1992;339:1128-30.
37. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10.
38. Polyzos SA, Kountouras J, Zavos C, et al. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011;16:79-88.
39. Polyzos SA, Kountouras J, Zavos C, et al. Comment on: Jeon et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012;35:520-525; e53; author reply e54.
40. Iwasaki M, Otani T, Yamamoto S, et al. Background characteristics of basic health examination participants: the JPHC Study Baseline Survey. J Epidemiol 2003;13:216-25.